二甲双胍与成人糖尿病患者下呼吸道疾病死亡率降低相关
该研究基于美国NHANES 1988-1994和1999-2010数据,纳入5266例40岁及以上糖尿病患者,随访至2011年。调整年龄、性别、种族、吸烟、BMI、哮喘、COPD、胰岛素及其他降糖药和糖化血红蛋白后,二甲双胍使用与下呼吸道疾病(CLRD)死亡率降低相关(HR 0.39,95%CI 0.15-0.99),基线CLRD患者中HR为0.30(95%CI 0.10-0.93)。
要点
- 二甲双胍使用与糖尿病患者下呼吸道疾病死亡率降低独立相关。
- 基线已有下呼吸道疾病者中该关联更明显(HR 0.30)。
- 其他降糖药未显示与下呼吸道疾病死亡率相关。
核心结论
- 在美国代表性样本中,二甲双胍使用与成人糖尿病患者下呼吸道疾病死亡率降低相关。
研究设计与样本
- 研究分析美国NHANES 1988-1994和1999-2010数据,纳入5266例40岁及以上糖尿病患者,随访至2011年,中位随访6.1年。
主要发现
- 二甲双胍使用率为31.9%,随访期间1869例死亡,其中72例死于下呼吸道疾病。
- 调整协变量后,二甲双胍与总体人群下呼吸道疾病死亡率降低相关(HR 0.39,95%CI 0.15-0.99)。
- 基线有下呼吸道疾病者中,二甲双胍与下呼吸道疾病死亡率降低相关(HR 0.30,95%CI 0.10-0.93)。
- 其他降糖药与下呼吸道疾病死亡率无关联。
临床怎么用
- 对合并糖尿病的呼吸科患者,二甲双胍使用史可能提示下呼吸道疾病死亡风险较低。
- 该关联为观察性结果,不能作为处方二甲双胍预防下呼吸道疾病死亡的依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Chronic lower respiratory diseases (CLRD) increase the risk of type 2 diabetes, which in turn may worsen lung function. Metformin, a common antidiabetic with anti-inflammatory and antioxidant properties, may improve respiratory outcomes. Therefore, we examined the association of metformin use with the risk of mortality from CLRD. METHODS: We analysed data from the National Health and Nutrition Examination Survey during 1988-1994 and 1999-2010 for participants aged 40 years or older who had diabetes and were followed up for mortality through 2011. Information on prescription medicine was collected at baseline and CLRD-related mortality during follow-up was defined using the 10th Revision of the International Classification of Diseases (ICD-10). Cox proportional hazards modelling was used to determine the mortality hazard ratio (HR) associated with metformin use, adjusting for relevant covariates. RESULTS: A total of 5266 participants with a median follow-up of 6.1 years were included. The prevalence of metformin use was 31.9% and 1869 participants died during follow-up, including 72 of CLRD. In the adjusted Cox proportional regression analysis, metformin was associated with a decreased risk of CLRD mortality in the overall population (HR: 0.39, 95% CI: 0.15-0.99) and among participants with baseline CLRD (HR: 0.30, 95% CI: 0.10-0.93), after adjusting for age, gender, race/ethnicity, cigarette smoking, body mass index, current asthma and chronic obstructive pulmonary disease (COPD), insulin and other diabetic medications, and glycohaemoglobin level. We found no association between other antidiabetic medications and CLRD mortality. CONCLUSION: In this sample representative of the U.S. population, metformin was associated with lower CLRD mortality in adults with diabetes.
引用
- Mendy A, Gopal R, Alcorn JF, et al. Reduced mortality from lower respiratory tract disease in adult diabetic patients treated with metformin. Respirology. 2019. PMID: 30761687. doi:10.1111/resp.13486
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。